Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01164475 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms
A Phase 4 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 61
- Enrollment target
NCT01164475 is a Phase 4 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 61 participants.
The verdict
NCT01164475, a Phase 4 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 61 participants
- Enrollment target
Study Summary
The purpose of this study was to compare the responses of 2 different doses of plerixafor in patients with Non-Hodgkin's Lymphoma (NHL) who received an autologous stem cell transplant.
Interventions
- DRUG Granulocyte-colony stimulating factor (G-CSF)
- DRUG Fixed Dose Plerixafor
- DRUG Weight-Based Plerixafor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 61 participants |
| Start Date | 2010-10 |
| Est. Completion | 2013-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01164475
The ClinicalTrials.gov registry entry for NCT01164475 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Granulocyte-colony stimulating factor (G-CSF) is the first listed.
NCT01164475 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01164475 about?
NCT01164475 is a clinical study titled "Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms". The purpose of this study was to compare the responses of 2 different doses of plerixafor in patients with Non-Hodgkin's Lymphoma (NHL) who received an autologous stem cell transplant.
What is the current status of trial NCT01164475?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 61 participants. The study started on 2010-10. Estimated completion is 2013-02.
What interventions are being tested in trial NCT01164475?
The interventions under investigation include: Granulocyte-colony stimulating factor (G-CSF) (DRUG), Fixed Dose Plerixafor (DRUG), Weight-Based Plerixafor (DRUG).
Who is sponsoring clinical trial NCT01164475?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.